The development of biologically active medication to treat TBC patients Malkov S. А., Shironosov...

The development of biologically active medication to treat TBC patients

Malkov S. А., Shironosov O.V., Shironosova G.I.

PROBLEM TOPICALITY

Every year TBC causes the following:

1 billon people

infection; 8-10 billion people

illness; 3-4 billion people death.

WHO declared TBC the global danger in 1993.

Is expensive (the average cost of one bed day - 1600 rubles);

Causes poisonous effect; Requires long-term (4-6

months) administration; Is aggravated by

multidrug resistance.

Modern TBC patient treatment

Galleria Mellonella – The Greater Wax Moth

I.I. Mechnikov (1889); S.А. Mukhin (1955); N.А. Spiridonov (1989).

Extract's properties:1. Immune protective;2. Antimicrobial;3. Antioxidant.

HOW TO GET A BIOACTIVE PRODUCT FROM THE GREATER WAX MOTH LARVAE(21)4938002/14 (22) 2603.91 (46)2706.95 Bulletin №18 (71) Institute of Theoretical and Experimental Biophysics, USSR Academy of Sciences(72) Spiridonov NA; Rachkov AK; Mukhin SA; Kondrashova MN. (73) Spiridonov Nikolay Aleksandrovich(55) USSR certificate of authorship N 1284229, 61 35/04. 1989. А К

The way of noncontact activation

Solutions with negative redox potential

THE PROJET’S AIM

is the development of bioactive medication (with long-lasting redox potential) on the basis of water solutions of The Greater Wax Moth larvae to treat TBC patients.

DYNAMICS OF REDOX POTENTIAL CHANGE

Date 09.07.11 12.08.11 18.08.11 24.08.11 06.09.11

Control (redox potential , mV)

80 84 82 79 83

Experiment (redox potential , mV)

-193 -248 -301 -445 -476

Clinical research

Republican tuberculosis dispensary:

15 patients; Infiltrative TB. Average age - 40 years; Gender - male; Treatment duration – 3,5

months.

Research results

twofold reduction of abacillary duration;reduction of intoxication;improvement of blood value (reduction of the number of lymphocytes, improvement of differential blood cell count, ESR reduction, etc.).

Commercialization perspectives

Bed day shortening by 1,5-2 times.

Treatment course depreciation.

Increase of medication’s biological activity .

Demand assessment after launching

Demand assessment after launching:

1st year (USD) 3rd year (USD)

Russia 50 000 200 000

CIS countries 70 000 300 000

ЕС countries, USA 100 000 350 000

GRNT - GLOBAL RESONANCE NONLINEAR TECHNOLOGIES

Thank You

and

Be Healthy!

http://grnt.biz